This FDA-registered laboratory represents a strategic acquisition opportunity in the specialized antimicrobial and antibiotic testing sector. With over 35 years of operational excellence, the facility has established itself as a trusted analytical partner to prestigious institutions and Fortune 500 companies.

The laboratory maintains active relationships with regulatory bodies including the U.S. Pharmacopeia (USP), European Pharmacopeia (EP), and World Health Organization (WHO), conducting potency assessments for antibiotic reference standards. The client portfolio includes major corporations such as DuPont, Johnson & Johnson, Calvin Klein, L'Oreal, and Church & Dwight.

CORE CAPABILITIES:
• Antibiotic Potency Testing (21-CFR/USP81 compliant)
• Cylinder plate and turbidimetric methodologies
• Antimicrobial evaluation across medical, industrial, and household products
• Microbial limits testing (CTFA/USP standards)
• Comparative potency assays
• Release testing for oral, topical, injectable, and ophthalmic formulations

PROPRIETARY TECHNOLOGIES:
The laboratory has developed several innovative testing methodologies that provide competitive advantages:
• Accelerated 4-hour cylinder plate diffusion assay (USP 81 compliant) versus industry standard 18-24 hours
• Advanced microbial immobilization techniques for enhanced assay performance
• High-sensitivity antimicrobial screening (300x enhancement) for comprehensive microbial coverage
• Rapid neutralization microbial limits testing
• Fourth-generation automatic Zone Reader intellectual property with commercialization potential in the $2+ billion testing equipment market

FINANCIAL PERFORMANCE:
Historical revenue has ranged from $500,000 to $800,000 annually. Recent revenue of less than